Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Mary-Kate MalecekMarcus P WatkinsNancy L BartlettPublished in: Expert opinion on biological therapy (2020)
The recent approval of polatuzumab vedotin in combination with bendamustine and rituximab (BR) offers another option to patients with DLBCL who are not eligible for autologous hematopoietic cell transplant or chimeric antigen receptors (CAR)-T cell therapy. In younger patients and those without serious comorbidities, polatuzumab vedotin-BR may serve as bridging therapy to more intensive therapies with reasonable efficacy and tolerability. Polatuzumab vedotin is currently being studied in a randomized trial in the front line setting in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
Keyphrases
- diffuse large b cell lymphoma
- cell therapy
- hodgkin lymphoma
- epstein barr virus
- stem cells
- mesenchymal stem cells
- end stage renal disease
- ejection fraction
- newly diagnosed
- bone marrow
- peritoneal dialysis
- chronic kidney disease
- prognostic factors
- low dose
- open label
- cancer therapy
- patient reported outcomes
- drug delivery
- randomized controlled trial
- clinical trial
- acute lymphoblastic leukemia
- replacement therapy
- smoking cessation
- double blind